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Abstract 
Steroid conversion (HSD11B1, HSD11B2, H6PD) and receptor genes (NR3C1, NR3C2) were examined 
in kidney-transplant recipients with “operational tolerance” and chronic rejection (CR), 
independently and within the context of 88 tolerance-associated genes. Associations with cellular 
types were explored. Peripheral whole-blood gene-expression levels (RT-qPCR-based) and cell 
counts were adjusted for immunosuppressant drug intake. Tolerant (n=17), stable (n=190) and CR 
patients (n=37) were compared. Healthy controls (n=14) were used as reference. The anti-
inflammatory glucocorticoid receptor (NR3C1) and the cortisol-activating HSD11B1 and H6PD genes 
were up-regulated in CR and were lowest in tolerant patients. The pro-inflammatory 
mineralocorticoid gene (NR3C2) was downregulated in stable and CR patients. NR3C1 was associated 
with neutrophils and NR3C2 with T-cells. Steroid conversion and receptor genes, alone, enabled 
classification of tolerant patients and were major contributors to gene-expression signatures of 
both, tolerance and CR, alongside known tolerance-associated genes, revealing a key role of steroid 
regulation and response in kidney transplantation. 
 
Keywords  
steroid receptor genes; steroid conversion; transplantation; kidney; tolerance; chronic rejection   
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1 Introduction 
Glucocorticoids (GC) act as immunosuppressants (IS) when administered in high, pharmacological 
doses, but play a complex role in the regulation of the innate and allogeneic immune response in 
lower, physiological doses. They show immunomodulatory effects and activate regulatory T-cells 
(Treg) (Dimeloe et al., 2010), which are involved in the establishment and maintenance of graft 
tolerance. Although graft tolerance is largely maintained by IS treatment, in extremely favourable 
cases IS can be completely withdrawn and graft tolerance retained (“operational tolerance”) (Lerut 
and Sanchez-Fueyo, 2006,Roussey-Kesler et al., 2006). On the other hand, despite being maintained 
on IS, kidney transplant recipients (KTR) frequently develop features of chronic rejection (CR), which 
is associated with graft dysfunction and leads to graft failure (Heemann and Lutz, 2013). 
Exogenous GC are fundamental for IS regimens in KTR. Despite refraining from high doses due to 
metabolic side effects, the benefits of withdrawal from low GC doses remain debatable (Steiner and 
Awdishu, 2011). Systematic clinical trials have demonstrated little benefit in steroid withdrawal, 
whilst increasing the risks of rejection (Haller et al., 2016). GC effects have, traditionally, been 
associated with their levels in the circulation, but the importance of local intracellular regulation is 
gaining appreciation (Hardy et al., 2012). 11-Hydroxysteroid dehydrogenases (11-HSDs) play a key 
part in the intracellular regulation of pre-receptor GC bioavailability via interconversion of the active 
cortisol to the inactive cortisone. 11-HSD1 (HSD11B1 gene) activates GC and, due to its intra-
luminal orientation in the endoplasmic reticulum, is regulated by the availability of the proton 
donor, supplied by the endoluminal hexose-6-phosphate dehydrogenase (H6PD) (Odermatt et al., 
2006). 11-HSD2 (HSD11B2) inactivates GC and, due to its cytoplasmic orientation on the 
endoplasmic reticulum membrane, ensures protection of the mineralocorticoid receptor (MR) from 
GC action (Odermatt et al., 2001). GC regulation by 11-HSDs has been demonstrated in lymphoid 
organs (Hennebold et al., 1996) and lymphocytes (Zhang et al., 2005). These enzymes also regulate 
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the interconversion of prednisolone and prednisone (Diederich et al., 2002) and can affect clinical 
outcomes by contributing to GC resistance (Sai et al., 2011). 
GC exert their main action via the glucocorticoid receptor (GR) (NR3C1), which plays a fundamental 
anti-inflammatory role (Baschant and Tuckermann, 2010) and interacts via tethering with 
immunoregulatory transcription factors (Ratman et al., 2013). There is a clear evidence that 
hindered in vitro response to exogenous GC and GC resistance in dialysis patients with chronic 
kidney disease pre-transplantation are associated, in the long-term (Frezza et al., 2014), as well as in 
the short-term (De Antonio et al., 2008), with higher incidence of acute rejection and poor allograft 
outcomes post-transplantation. Conversely to the anti-inflammatory role of GR, a pro-inflammatory 
role of the MR (NR3C2) is becoming apparent (Bene et al., 2014). MR activation has been associated 
with activation of pro-inflammatory Th17 cells and a downregulation of the tolerance and T-reg-
associated FOXP3 gene (forkhead box P3) in peripheral blood mononuclear cells (PBMC) and kidney 
and a decrease of FOXP3-positive CD4+ cells (Amador et al., 2014). 
Given the high importance of GC action for transplantation outcomes and the importance of 
endogenous GC conversion for GC action, it is surprising that studies on the role of endogenous GC 
conversion and GC response independent of exogenous GC administration are scarce in 
transplantation research and that largely only the effects of exogenous steroids on lymphocyte 
populations have been considered (Berki et al., 2002,Ribarac-Stepic et al., 2001). 
We, therefore, set to examine the role of endogenous GC conversion and steroid response in 
patients with established kidney grafts for several years post transplantation. We hypothesised that 
the state of “operational tolerance” is maintained via activated anti-inflammatory processes and 
hindered pro-inflammatory processes, which is reflected in upregulated GR and GC activation and 
downregulated MR and GC inactivation in tolerant compared to stable KTR. In CR, as a process 
physiologically opposite to tolerance, with a maintained pro-inflammatory state despite IS 
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treatment, we expected changes in the opposite direction, i.e. domination of pro-inflammatory 
processed and hindered or absent anti-inflammatory responses.  
We examined the expression of steroid conversion (HSD11B2, HSD11B1, H6PD) and receptor genes 
(NR3C1, NR3C2) in peripheral whole blood of KTR with “operational tolerance” or with CR and in 
clinically stable patients maintained on IS according to local clinical practice. We evaluated whether 
differences in the expression of steroid conversion and receptor genes would be sufficiently large to 
enable discrimination between clinical groups of transplanted patients and whether these genes 
would remain informative within the context of known tolerance-associated genes and, hence, could 
contribute to clinically-applicable gene-expression signatures of tolerance and CR. To account for the 
effect of exogenous drug administration, i.e. to evaluate features associated with tolerance, as 
opposed to differences arising from the absence of IS medication in patients with “operational 
tolerance”, and to evaluate features of CR, as opposed to differences driven by the IS regimens, we 
used drug-adjusted gene-expression levels, as previously (Rebollo-Mesa et al., 2016), and extended 
this approach to cell counts, after exploring the influence of prednisolone treatment on steroid 
conversion and receptor genes and demonstrating the effect of drug-adjustment. 
Finally, since the main molecular assay that we used was indiscriminate to GR isoforms (+), we 
examined separately mRNA expression of GR. Whilst GR does not directly regulate GC-responsive 
genes, when co-expressed with GR it functions as a dominant-negative inhibitor of the effects of 
GR on GC-regulated genes (Oakley and Cidlowski, 2011) and, thus, is involved in the development 
of GC-resistance. It was of interest to examine whether there is evidence of GC-resistance or lack of 
GC response in CR, as this might explain why IS treatment, which often includes an exodenous GC, 
fails to suppress pro-inflammatory processes in CR.  
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2 Materials and Methods 
2.1 Patients and Samples 
Samples originated from KTR in the GAMBIT study (Genetic Analysis of Molecular Biomarkers of 
Immunological Tolerance, Research Ethics Reference: 09/H0713/12). The cohort included four 
clinical groups: tolerant, stable and CR patients and healthy controls (HC). The rational for patient 
classification, patient characteristics and IS regimens have previously been described (Rebollo-Mesa 
et al., 2016). Only patients treated with any of the following IS drugs were included: prednisolone, 
calcineurin inhibitor (CNI) (cyclosporine of tacrolimus), anti-proliferative agent (azathioprine or 
mycophenolate-mofetil (MMF)). Patients receiving other IS drugs were few and were excluded from 
the selection, to enable a more robust drug-adjustment. 
Steroid receptor and conversion genes were examined in a total of 258 individuals (timepoint 1 (T1 
cohort) samples): 17 tolerant (5 additional to our previous study), 190 stable, 37 CR patients and 14 
HC. A second set of samples (timepoint 2 (T2 cohort)) (collected after a median of 182 days following 
the first sample, inter-quartile range (IQR) 126 – 233 days) was available for 82 of these individuals 
(13 tolerant, 45 stable, 16 CR patients and 8 HC). Glucocorticoid receptor -isoform mRNA 
expression was examined in T1 samples from 167 individuals (12 tolerant, 123 stable, 24, CR patients 
and 8 HC). Tolerance-associated genes were analysed in T1 samples for 229 of the individuals (13 
tolerant, 171 stable, 34 CR patients and 11 HC) and in 52 of those (10 tolerant, 26 stable and 16 CR 
patients) also in T2 samples. Blood cell counts were available for T1 samples of KTR as follows: 
neutrophil counts in 186 patients (9 tolerant, 144 stable, 33 CR); T-cell counts in 96 patients (8 
tolerant, 65 stable, 23 CR); B-cell counts in 87 patients (10 tolerant, 58 stable, 19 CR). 
An independent steroid-withdrawal cohort comprised 28 patients providing a sample prior to 
initiation of prednisolone withdrawal and after a median of 209 days (IQR 131 – 254 days) post 
withdrawal completion. The withdrawal was conducted due to clinical reasons or according to local 
standard clinical practice and took place over a median period of 115 days (IQR 75 – 164 days). The 
median prednisolone dose was 3 mg per day (IQR 3 – 5.6 mg) and the accompanying IS drugs were 
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MMF (both timepoints) and CNI (12 cyclosporine and 15 tacrolimus at both timepoints, one patient 
switched from cyclosporine to tacrolimus). Neutrophil counts were available for 22 of these patients. 
2.2 Gene-expression and flow-cytometry analysis 
Peripheral vein blood was collected into Tempus™ Blood RNA Tubes (Life-Technologies). Steroid 
conversion and receptor genes were analysed with RT-qPCR (Applied Biosystems). Fluidigm 
(BioMark) RT-qPCR platform was used, with a pre-amplification step, to analyse 3 endogenous 
reference genes and 93 tolerance-associated genes (Table S1). These were compiled from our 
previous analysis of microarrays (28 genes, which contributed to the development of our-previously 
published signature of tolerance (Rebollo-Mesa et al., 2016)) and from literature sources (65 
additional tolerance-associated genes). Neutrophil counts were obtained from routine 
haematological differential blood-cell counts. Lymphocyte subset counts were derived from flow-
cytometry analysis of PBMC. Sample storage, RNA isolation, cDNA synthesis, RT-qPCR and Fluidigm 
conditions, antibody panels and acquisition details for flow cytometry have previously been 
previously described in detail (Rebollo-Mesa et al., 2016). Samples from a given clinical group and IS 
regimen were distributed over all analytical plates, to avoid batch effects determining group or drug 
differences. Pre and post withdrawal samples were analysed in the same plate. Five tolerance-
associated genes with unsatisfactory reproducibility in Fluidigm analysis (missing in over 25% of the 
samples) were excluded. HSD11B2 was detected in 88.9% of the samples, albeit above the 
conventional threshold for positive RT-qPCR determination of 35 Ct. GR mRNA expression was also 
above 35 Ct in the examined samples. Relative gene-expression values were calculated on log2 scale 
with the –Ct method (Schmittgen and Livak, 2008) relative to HPRT (hypoxanthine 
phosphoribosyltransferase), used as reference gene in steroid (Bisschop et al., 2013) and 
transplantation research (Rebollo-Mesa et al., 2016). 
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2.3 Statistical analysis 
Statistical analysis was performed in R version 3.2.2 (RCoreTeam, 2015). Outliers were recoded to 
the next highest or lowest value prior to parametric analyses. Missing gene expression data were 
imputed with K-nearest neighbour for microarrays (Troyanskaya et al., 2001) (package impute 
(Hastie, 2015)) prior to multivariable analyses. P-values were interpreted as an estimate of the 
strength of evidence rather than in a relation to a significance cut-off. 
2.3.1 Drug-adjustment strategy 
We have previously demonstrated that intake of IS drugs affects gene-expression levels and 
signatures and warrants adjustment of gene-expression values for IS drug intake. Cell counts can 
also be influenced by drugs (Nakagawa et al., 1998,Tareyeva et al., 1980) and would, similarly, 
require adjustment for immunosuppressant intake. We used a binary indicator for prednisolone 
intake and categorical indicators for intake of CNI (off, cyclosporine, tacrolimus) and anti-
proliferative drugs (off, azathioprine, MMF). 
In order to differentiate the effects of exogenous steroids from the endogenous mechanisms 
involved in tolerance in CR, we first examined the effect of prednisolone on unadjusted gene-
expression values and cell counts, taking into account the intake of other IS drugs. We then 
regressed-out the effects of all IS drugs and generated drug-adjusted residuals using linear 
regression models based only on stable patients, to avoid obliterating differences with tolerant or CR 
patients if analysed jointly. Drug adjustment resulted in centring the data relative to the mean in 
stable patients, whilst retaining the original unit of measurement. 
To compare unrelated patients on and off prednisolone, adjusting for confounding by drugs other 
than prednisolone, we used linear regression models with categorical indicators for drug intake. To 
compare samples pre and post prednisolone withdrawal in patients from the steroid-withdrawal 
cohort, adjusting for confounding by drugs other than prednisolone, we used linear mixed-effects 
models with a random intercept and fixed effects for the indicators of drug intake. 
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2.3.2 Comparison between clinical groups 
To compare individual variables between clinical groups, we used Wilcoxon-Mann-Whitney test. 
While single-variable comparisons are easy to visualise and appear more intuitive to the biomedical 
audience, they consider individual components in isolation. Therefore, to account for the fact that 
genes act in combination within the organism, i.e. conditional on the levels of expression of each 
other, and to accommodate multiple, potentially correlated genes in one group-discrimination 
model, we used multivariable penalised logistic regression with an elastic net penalty (package 
glmnet (Friedman et al., 2010)). Within a multivariable model, the perturbations in the expression 
levels of a given gene between two groups are compared among individuals with equal levels of 
expression of the other examined genes, i.e. accounting for the effect of the rest of the genes 
included in the model. Further, the elastic net penalty enables a statistical selection of genes 
relevant to a given association and exclusion (by shrinking of the regression coefficients to zero) of 
genes with minimal or no contribution to discrimination between clinical groups, while at the same 
time allowing the inclusion of groups of strongly-correlated genes in the gene-expression signatures 
(models). Consequently, to evaluate the importance of each gene, conditional on the expression of 
all examined genes, we used the absolute value of the penalised regression coefficients. Only genes 
selected by the penalised regression procedure were considered informative for group 
discrimination (“classification-informative”). We set the penalty parameter alpha to 0.7 which, in our 
experience, gives a good balance between the number of classification-informative and strongly-
correlated genes selected in a signature. The second penalty parameter (lambda) was determined as 
the median of 100 repeats of five-fold cross-validation cycles (function cv.glmnet (Friedman et al., 
2010)). 
To identify features of tolerance and CR we compared, correspondingly, tolerant with stable patients 
(TvS) and CR with stable patients (CvS). T1 samples provided the training dataset. 
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To minimise overfitting, we derived the regression coefficients of each of the final group-
discrimination models (“median models”) as the medians of the penalised regression coefficients of 
50 group-stratified repeats of five-fold cross-validation cycles and summarised the variability with 
IQR and the 2.5th - 97.5th centile range. Unlike classical regression, modern statistical methods such 
as elastic net penalised regression do not provide p-values. However, evaluating the variability of 
regression coefficients with cross-validation provides a better measure of the generalisability of the 
findings. The interpretation of the summaries of regression coefficients derived via cross-validation 
is as follows: genes with non-zero IQR of the regression coefficients would be considered of 
particular importance for group discrimination, because these had been selected as informative 
(different from zero) in more than half of the multivariable gene-expression signatures derived from 
repeats of the cross-validation cycles. Furthermore, genes with a non-zero 2.5th - 97.5th centile range 
of the regression coefficients had been selected as informative in more than 95% of the models, 
hence the highest importance. 
To evaluate model performance, we used the area under the receiver operating characteristics curve 
(AUC) for the predicted probability of tolerance or CR. 
2.3.3 Validation strategy 
To confirm observations of exogenous steroid effects based on stable patients on and off 
prednisolone, we compared the paired samples from the patients in the steroid-withdrawal cohort, 
as well as samples from CR patients on and off prednisolone. 
To evaluate whether the drug-adjustment approach has accounted for exogenous steroid effects in 
samples unseen in the development of the drug-adjustment models (based only on stable patients), 
we compared the drug-adjusted residuals in the paired samples of the patients in the steroid-
withdrawal cohort and in the CR patients on and off prednisolone. 
To validate our gene-expression signatures, we used the following approaches: 
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First, we performed cross-validation with the training T1 datasets. A cross-validated AUC (CV.AUC) 
was calculated for the predicted probabilities of tolerance and CR for unseen data in five-fold cross-
validation cycles, in which all steps of model development, including generation of drug-adjusted 
residuals, imputation of missing data and outlier correction, were performed with the training sub-
set and the left-out unseen test subset was used solely for model evaluation. CV.AUC obtained in 50 
repeats of the cross-validation cycles was summarised with median and 2.5th - 97.5th centile range. 
Second, we used samples from the KTR groups not participating in the given group-discrimination 
model, i.e. samples from CR patients were unseen for the development of the tolerance signatures 
and samples from tolerant patients were unseen for the development of the CR signatures. Given 
that some stable KTRs may be potentially tolerant and others experiencing subclinical or early stages 
of CR, i.e. there is an overlap between the training clinical groups, we expected that a 
mechanistically relevant signature would achieve a better discrimination between tolerant and CR 
patients compared to the discrimination achieved between tolerant and stable patients or between 
CR and stable patients, as tolerant and CR patients would not be overlapping. Similarly, HC did not 
participate in the development of the group-discrimination models. These were compared only with 
tolerant patients as a drug-free and transplantation-free reference. 
Third, we used the unseen samples from the T2 test dataset, which were analysed separately and 
had not participated in any model development. 
2.3.4 Gene-gene-cell associations 
To evaluate associations between steroid conversion and receptor genes, classification-informative 
tolerance-associated genes and absolute blood cell counts, we used Pearson regression coefficients 
and applied hierarchical cluster analysis to the gene-cell correlation matrix using Ward’s minimum 
variance linkage method (Murtagh and Legendre, 2014). We also examined matches of classification-
informative genes with gene sets included in the collections of the Molecular Signatures Database 
v5.1 (Broad Institute) (Subramanian et al., 2005).   
16 
 
3 Results and Discussion 
3.1 Prednisolone intake affects gene expression and cell counts, which is accounted 
for in drug-adjusted residuals  
To evaluate the effect of prednisolone, we compared the expression of steroid conversion and 
receptor genes in samples from stable patients on and off prednisolone, adjusting for CNI and anti-
proliferative drug intake (Figure S1A-E). In prednisolone-treated patients HSD11B1 (p=0.006) and 
NR3C2 (p=0.027) expression were lower, H6PD expression was somewhat higher (p=0.098), whilst 
there was no evidence for a difference in HSD11B2 (p=0.676) and NR3C1 (p=0.510) expression, 
contrary to a reported down-regulation of GR binding sites in PBMC with pulse GC administration 
(Andreae et al., 2001). However, comparison of GR levels in kidney transplant patients has 
previously demonstrated that a reduction of GR levels is observed only in patients treated with high 
booster doses of GC and not in patients treated long-term with lower doses (Berki et al., 2002), 
which is in agreement with our findings of no difference in NR3C1 expression off and on long-term 
prednisolone treatment. The comparison of paired samples on and off prednisolone from the 
steroid-withdrawal cohort confirmed our observations in stable patients (Figure S1F-J), with the 
exception of HSD11B2 expression, which showed a tendency to be higher with prednisolone 
treatment (p=0.084). To examine whether the latter effect was driven by IS drugs other than 
prednisolone, we examined a subset of the T1 cohort with IS regimen matching that of the steroid-
withdrawal cohort (on CNI and MMF). This confirmed the results of the complete set of stable 
patients, as did the comparison of CR patients on and off prednisolone (Figure S1K-O).  A key 
difference between the steroid-withdrawal and the stable patients was the time post 
transplantation, with no overlap between the two groups (median 1.2 years (min 6 days – max 3.1 
years) compared to median 13.0 years (4.2 – 36.7 years)) respectively, which could be responsible 
for the difference.  
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We then generated drug-adjusted residuals (as described in Section 2.3.1) and re-examined 
differences on and off prednisolone (p-values in brackets in Figure S1). Prednisolone effects were 
accounted for in all groups and for all genes, except HSD11B2 expression in the steroid-withdrawal 
cohort, as this was not observed in the stable patients informing the drug-adjustment models 
(Figure S1C,H). 
Further, we examined the effect of prednisolone on neutrophil cell counts, adjusting for CNI and 
anti-proliferative drug intake. As anticipated, based on literature reports (Nakagawa et al., 1998), 
there was evidence for an increase in neutrophil counts with prednisolone treatment in all patient 
groups (Figure S2), which was accounted for in the drug-adjusted counts (p-values in brackets Figure 
S2). 
Having demonstrated that prednisolone effects are accounted for in drug-adjusted residuals, it was 
justifiable to proceed with interpreting differences between clinical groups observed in drug-
adjusted gene-expression levels and cell counts as driven by endogenous processes related to 
tolerance and CR and not to exogenous steroid treatment. Confining the study to patients with 
prednisolone-free drug regimen would not have been appropriate, as other IS drugs also affect 
gene-expression and cell counts (Nakagawa et al., 1998,Rebollo-Mesa et al., 2016,Tareyeva et al., 
1980) and, therefore, adjustment for all IS drugs is warranted. Similarly, using steroid-treated 
patients with a different condition would not have been appropriate, because these would have 
carried features of their underlying condition (most likely with an immunological inflammatory 
component, if it requires steroid treatment) in addition to features of prednisolone intake. 
3.2 Expression of steroid conversion and receptor genes alone could differentiate 
tolerant and chronic rejection patients 
We next examined differences in the drug-adjusted expression of individual steroid conversion and 
receptor genes (Figure 1) between clinical groups, in order to gain information on the net 
contribution of individual genes to group discrimination. There was evidence for higher expression 
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of HSD11B1, H6PD and NR3C1 in stable and CR compared to tolerant patients (Figure 1A,B,D), while 
the NC3R2 showed changes in the opposite direction and was low in CR and stable patients (Figure 
1E). NR3C1 upregulation and NR3C2 downregulation was universal for KTR compared to HC and was 
especially pronounced in the relative expression NR3C1v2 (defined as the difference on a log2 scale, 
equivalent to the ratio on a linear scale), which was independent of the reference gene and was 
highest in CR and lowest in HC (Figure 1F). 
To evaluate the joint contribution of the steroid conversion and receptor genes to clinical group 
discriminations, we trained multivariable penalised logistic regression models (as explained in 
Section 2.3.2.) (Figure 2, Table S2) and used the median models to predict the probabilities of 
tolerance and CR for all examined clinical groups (Figure 3). The multivariable models further 
emphasised the group differences observed for individual genes (Figure 2, Figure 1).  
The tolerance signature achieved a very good discrimination of tolerant patients from each of the 
other clinical groups included in the validation (Figure 3B), as well as in the training dataset (Figure 
3A,B) (Table 1). Although all 5-genes were retained in the median tolerance signature, it is worth 
pointing out that the 2.5th -97.5th centile intervals of the penalised regression coefficients for 
HSD11B1 and the steroid receptor genes were well away from the gene-exclusion value of zero 
(Figure 2A). This means that the three genes were selected as classification-informative in at least 
95% of the cross-validation models, emphasising that whilst there is some variability between the 
features of individual patients, differences in the expression of the three genes are of major 
importance in the majority of them.  
The CR signature could separate, to an extent, CR from stable patients (Figure 3C,D), but the 
difference in the predicted probability of CR was insufficient to enable good discrimination between 
the clinical groups, although the performance of the CR signature in the validation dataset (T2) was 
better than in the training data (T1) (Table 1). Only HSD11B2 and NR3C1 were retained as 
classification-informative genes in the median CR signature (both higher in CR) (Figure 2B). 
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The predicted probabilities of tolerance and CR were more extreme in the clinical groups not 
participating in model development (Figure 3), i.e. the discrimination between tolerant and CR 
patients was excellent with the tolerance signature and very good even with the CR signature (Table 
1). 
3.3 Steroid conversion and receptor genes were main contributors to tolerance and 
chronic rejection signatures, alongside tolerance-associated genes 
Further, we examined whether steroid conversion and receptor genes would continue to contribute 
to the discrimination of tolerant and CR patients after the addition of 88 tolerance-associated genes 
(Table S3) to the multivariable penalised logistic regression models. Genes contributing to the 
combined gene-expression signatures  are shown in Figure 4 (listed in Table S3) and the predicted 
probabilities of tolerance and CR for all examined clinical groups are plotted in Figure 5 (group 
comparisons for the individual classification-informative tolerance-associated genes are plotted in 
Figure S3). The discrimination of tolerant from stable patients remained the same (Figure 5A,B), 
whilst the discrimination of CR from stable patients was considerably improved (Figure 5C,D) (Table 
1). Remarkably, representatives of the steroid conversion and receptor genes had prominent places 
among the 17 genes informative for tolerance (Figure 4A) and the 15 genes informative for CR 
discrimination (Figure 4B). The discrimination between tolerant and CR patients with either 
signatures was excellent (CV.AUC above 0.930, Table 1). Reassuringly, gene-expression signatures 
were not influenced by prednisolone intake (Figure S4), re-affirming the merits of drug-adjustment. 
Among all classification-informative genes in the tolerance signature, HSD11B1 had the largest and 
most consistent contribution to the discrimination between clinical groups (narrow 2.5th-97.5th 
centile interval) (Figure 4A), even larger than that of well-established tolerance-associated genes 
such as the T-reg-activation gene FOXP3 (Sagoo et al., 2010) or the B-cell receptor genes IGKV4-1 
and IGKV1D-13 (Moreso et al., 2014). In support of a mechanistic involvement of HSD11B1 in 
tolerance, a change in the opposite direction (an increase in 11-HSD1 enzyme activity) has been 
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associated with activation of CD4+ T-cells and polarisation into Th1 or Th2 cells (Zhang et al., 2005), a 
process which would be reduced in tolerance. In steroid target tissues HSD11B1 is co-expressed with 
the GR-gene (NR3C1) (Tomlinson et al., 2004), coupling cortisol activation to GR availability. This 
agrees with our findings of concomitantly low NR3C1, HSD11B1 and H6PD expression in tolerant 
compared to stable and CR patients (Figure 1, Figure 2). In addition, HSD11B1 and STAT1 (low in 
tolerant patients, Figure 4A), along with CISH and C1s (high in CR patients, Figure 4B), were among 
genes down-regulated in CD4:FOXP3+ T-reg compared to FOXP3 knockout T-reg precursors 
(Samstein et al., 2012,Subramanian et al., 2005), suggesting that HSD11B1 downregulation is 
coupled with T-reg activation. Further, GC treatment has been associated with increased FOXP3 
expression in vivo and, along with IL-10, in vitro (Karagiannidis et al., 2004). While FOXP3 expression 
is not exclusively attributable to T-reg (Prado et al., 2011) and a transient state of T-reg functionality 
(with increased FOXP3 and IL-10 expression) is observed in all activated human T-cells (Pillai et al., 
2007), higher FOXP3 expression was a consistent feature of our tolerant patients (Figure 4), in which 
the immune responses would have reached a longer-term equilibration and, therefore, FOXP3-
associated pathways would be derived from immune-suppressive T-reg cells. Therefore, given that 
“operationally tolerant” patients do not receive exogenous steroids, we can conclude that they have 
an adequate supply of endogenous cortisol. 
Conversely, in CR patients, in which pro-inflammatory responses would be activated, steroid 
conversion and receptor genes showed changes in the opposite direction. NR3C1 expression was 
upregulated (Figure 1D), along with that of HSD11B2 (Figure 1C), and both genes were among the 
main contributors to the discrimination of CR patients (Figure 2B, Figure 4B). Strengthening the 
mechanistic argument, HSD11B2 and NR3C1 were part of a MAPK8-upregulated gene set 
(Subramanian et al., 2005,Yoshimura et al., 2005). MAPK8 plays a key role in T-cell proliferation, 
apoptosis and differentiation and assists polarized differentiation of pro-inflammatory Th1 cells 
(Arbour et al., 2002,Dong et al., 2001). At the same time, ligand-bound GR (NR3C1) interacts with 
the MAPK8 signaling pathway and modulates pro-inflammatory gene expression (Baschant and 
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Tuckermann, 2010), executing a negative feed-back regulation in situations of increased allo-antigen 
challenge. Given that gene expression in whole blood captures the net effect of multiple pathways, 
we would argue that NR3C1 upregulation is part of an anti-inflammatory response, activated in CR 
concomitantly to the pro-inflammatory pathways. We interpret this as an evidence for increased or 
unmet GC demand, a concept compliant with an inappropriately low serum cortisol relative to the 
levels of inflammatory factors described in chronic inflammation (Straub et al., 2002). In this regard, 
HSD11B2 upregulation in CR could be a response to pro-inflammatory cytokines leading to GC 
deactivation in immune cells in peripheral blood, but also in the kidney parenchyma, via induction 
from infiltrating cells, and this could be responsible for the development of GC resistance. Indeed, a 
larger proportion of CR patients already receive prednisolone (73% vs 43% in stable patients, 
p=0.002), yet they appear GC deficient. Another option for HSD11B2 activation could be to ensure 
that the GC effects within the immune cells are confined to GR, since the 11-HSD2 enzyme ensures 
cortisol inactivation within the vicinity of the pro-inflammatory MR (Odermatt et al., 2001). NR3C2 
itself was downregulated in CR and stable, compared to tolerant patients (Figure 1), which could 
reflect an attempt to re-gain tolerance, as MR induction has been associated with T-reg decrease 
(Amador et al., 2014), and to assist anti-inflammatory processes, as a macrophage-specific deletion 
of MR results in alternative activation and M2 polarisation of macrophages (Usher et al., 2010). A 
further argument in support of GC involvement in the activation of anti-inflammatory pathways in 
CR was the increased expression of TSC22D3 (Figure 4), a key GC-induced regulator of inflammation 
(Beaulieu and Morand, 2011), commonly known as GILZ (glucocorticoid-induced leucine zipper 
protein gene). GILZ protein exerts anti-inflammatory properties by inhibiting T-cell activation and 
nuclear factor kappaB (Ayroldi et al., 2001) and directs the differentiation of antigen-specific T-reg 
(Hamdi et al., 2007), outlining a role of GILZ gene, along with its inductor GR, in tolerance. The 
expression of GILZ (TSC22D3) gene was fairly strongly positively associated with the expression of 
NR3C1 gene (r=0.46, p=<0.001), more weakly with HSD11B2 gene (r=0.20, p=0.004), effectively not 
associated with HSD11B1 gene (r=0.03, p=0.70) and negatively associated with NR3C2 gene 
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expression (r=-0.21, p=0.002). Although we were not able to measure the GR protein levels or 
binding capacity or the activity of 11-HSDs, the fact that the increase of NR3C1 gene expression was 
paralleled by an upregulation of the GC-inducible GR-responsive GILZ gene and that both genes were 
considered by the statistical algorithm important for CR discrimination (Figure 4B), indicates that 
there is a true activation of the GC cascade with the involvement of GR protein synthesis and a GR-
mediated GC response, at least in some blood sell subtypes, in CR patients. 
3.4 Gene-cell associations 
Having unravelled an association of steroid conversion and receptor genes with tolerance and CR, 
we set to investigate possible associations between these and the classification-informative 
tolerance-associated genes, as well as with the main components of the cellular compartment of 
peripheral blood, using hierarchical cluster analysis of the Pearson correlation (r) matrix of drug-
adjusted gene-expression and cell counts (Figure 6, Figure S6). While tolerance-associated genes 
were, overall, strongly correlated with each other and formed two distinct clusters, steroid 
conversion and receptor genes were fairly isolated in separate clusters. Contrary to the reports of 
co-expression of NR3C1 and HSD11B1 in steroid target tissues (Tomlinson et al., 2004), there was 
only a very weak positive association of NR3C1 with HSD11B1 (r=0.13, p=0.037), but a very strong 
one with H6PD (r=0.75, p<0.001) instead (Figure 6). Despite the opposite changes in the expression 
of the GR and MR gene in tolerant and CR patients (Figure 1D-F), there was no direct negative 
association between them (r=0.024, p=0.708). There was, however, a positive association of the 
expression of NR3C1 with neutrophil counts (r=0.30, p<0.001) and a negative association with T-cell 
(r=-0.32, p=0.001) and total and transitional B-cell counts (both r=-0.34, p=0.001), while NR3C2 
expression was positively associated with T-cell (r=0.47, p<0.001) and less with total and transitional 
B-cell counts (r=0.21, p=0.046 and r=0.20, p=0.064) and negatively associated with neutrophil counts 
(r=-0.22, p=0.003), indicating an indirect link between NR3C1 and NR3C2 regulation. In addition, 
there was some decrease of T-cell counts in CR compared to stable patients (p=0.011, Figure S5B), 
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which may reflect an infiltration of a particular T-cell sub-set in the kidney, but there was no 
difference in neutrophil counts (p=0.892, Figure S5A). Drug-adjusted B-cell counts were higher in 
tolerant and lower in CR patients (Figure S5C,D) (similar to the un-adjusted counts (Rebollo-Mesa et 
al., 2016)) and were positively associated with the B-cell receptor genes IGKV4-1 (r=0.50, p<0.001 for 
total and r=0.29, p=0.008 for transitional B-cell counts) and IGKV1D-13 (r=0.42, p=0.001 and r=0.24, 
p=0.069) (Figure 6), as would be expected. 
Published reports indicate that peripheral blood lymphocytes from CR patients show lower number 
of GR binding cites and lower GR affinity for GC compared to stable patients (Ribarac-Stepic et al., 
2001), which would be in agreement with our findings of a negative association of NR3C1 expression 
with T and B-cell counts. The positive association of NR3C1 expression with neutrophil counts may 
explain why we have observed a net increase in NR3C1 expression in whole blood samples from CR 
compared to stable patients (Figure 1D, Figure 2B). The adjustment for drug intake that we have 
used would take care of differences potentially arising from prednisolone contribution to 
granulocytosis (Nakagawa et al., 1998), as shown in Figure S2, and we would, therefore, expect that 
true differences in neutrophils exist between CR and stable patients. 
3.5 Glucocorticoid resistance could be present in chronic rejection, related to 
upregulation of the GR isoform 
Having established NR3C1 as one of the main genes up-regulated in CR (based on GR+ mRNA 
expression), we set to examine the relative contribution of the alternatively spliced inhibitor isoform 
GR. Whilst the absolute levels of GR mRNA expression were low (in agreement with literature 
reports (Oakley and Cidlowski, 2011)), evidencing a clear upregulation of the GR isoform, the 
patterns of expression of the GR isoform followed those established for GR+ mRNA - there was 
no evidence for prednisolone effect (Figure S7A, similar to Figure S1D,I,N) and the drug-adjusted 
GR mRNA expression was particularly high in CR, but also in stable, compared to tolerant patients 
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(Figure S7B, similar to Figure 1D). Liang et al. have reported a reduced mRNA expression and protein 
levels for GR in PBMC for GC-resistant compared to GC-sensitive patients with immune 
thrombocytopenia and no difference in GR mRNA expression, which have led the authors to the 
conclusion that downregulation of GR levels may be involved in GC-resistance in this condition 
(Liang et al., 2016). Our findings in whole blood samples from CR patients bear more similarity to 
ulcerative colitis, where an increase of GR-positive cells and GR mRNA expression in colonic 
mucosa has been reported in GC-resistant compared to GC-sensitive patients, along with an increase 
of GR mRNA expression in both groups of patients compared to healthy controls, which have led 
these authors to propose that GR may be involved in GC-resistance in ulcerative colitis (Fujishima 
et al., 2009). Given that we have examined drug-adjusted gene expression values, which reveal 
endogenous, rather than prednisolone-driven processes (Section 3.1.), it is possible that pro-
inflammatory transcription factors in CR contribute to the development of steroid resistance via the 
inhibitory effect of GRon the GC response of GR. Indeed, a similar-fold increase in mRNA 
expression of both GR and GR isoforms has been described in cell lines in vitro in response to 
tumour necrosis factor (TNF), which resulted in a disproportionately larger increase in the steady-
state levels of the GR protein isoform compared to GR (Webster et al., 2001). Given that we have 
examined all blood cells jointly in a whole blood sample, it is also possible that GR and GR mRNA 
upregulation does not co-localise in the same cells and that a GR-conferred GC resistance in a 
particular cellular sub-type, most likely induced by pro-inflammatory cytokines, hinders the anti-
inflammatory attempts initiated by GR upregulation in a different cellular subtype and leads to an 
overall inefficiency of IS treatment in CR. The quantitative importance of GR gene up-regulation in 
CR warrants further investigation, especially in the light of the increased GR mRNA expression. A 
factor that could be contributing to GC resistance down-stream from GR gene expression is vitamin 
D, which when increased could inhibit the nuclear translocation of GR via alternative 
phosphorylation (Kassi et al., 2016). In kidney transplant recipients, however, vitamin D levels are 
often low (Cianciolo et al., 2016) and a vitamin-D-induced GC resistance may be of lesser importance 
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for them, unless high doses of exogenous vitamin D products are administered. Whist GC resistance 
developing during dialysis treatment prior to transplantation could also propagate into the post-
transplantation period and increase the risk of CR (De Antonio et al., 2008,Frezza et al., 2014), no 
data were available on the pre-transplantation status of our patients as they were recruited several 
years post-transplantation when tolerant patients are usually identified. 
4 Conclusions 
The expression of steroid conversion and receptor genes in peripheral blood of KTR showed 
differences in opposite directions to our original hypotheses. Increased steroid activation and 
response paralleled an anti-inflammatory demand, rather than indicated an advantageously high 
constitutive anti-inflammatory predisposition (HSD11B1, H6PD and NR3C1 genes were upregulated 
in CR and stable compared to tolerant patients). Conversely, the expression of the MR-gene 
reflected a suppression of pro-inflammatory processes in conditions of increased immunological 
challenge, rather than indicated an advantageously low constitutive pro-inflammatory state in 
“operational tolerance” (NR3C2 was downregulated in CR and stable compared to tolerant patients) 
(Figures 1,2,4). Our findings suggest that “operational tolerance”, rather than being a condition in 
which active pro-inflammatory processes are efficiently suppressed by GC-related anti-inflammatory 
responses, is a state in which the immune system does not appear to identify the graft as “foreign” 
and, hence, neither activation of the GC-related anti-inflammatory response nor suppression of the 
pro-inflammatory MR are required. Further, our data suggest that in some peripheral blood cells in 
CR GC-related anti-inflammatory responses are operating and the MR is suppressed and, hence, is 
less likely to contribute to the pro-inflammatory processes, but also, that in other cell types there is 
GC-resistance related to up-regulation of the suppressive GR isoform or the HSD11B2 gene 
involved in intracellular GC-inactivation.    
Using penalised logistic regression as a statistical learning tool we have demonstrated that steroid 
conversion and receptor genes have a place right into the heart of the immunological mechanisms 
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involved in tolerance and CR in KTR. It is impressive that tolerance signatures based only on steroid 
conversion and receptor genes showed similar performance at cross-validation to the gene 
signatures derived after addition of 88 tolerance-associated genes (Table 1). Expression of steroid 
conversion and receptor genes was poorly associated with other classification-relevant genes (Figure 
6), indicating their involvement within unexamined immunological networks. While these findings 
should not be unexpected, considering the central role that steroids play in immunoregulation and 
the anti-inflammatory response and the fact that that steroid treatment is fundamental to the 
maintenance IS regimens in KTR, it is surprising that studies of endogenous steroid conversion and 
response have not yet found a deserved place in the context of transplantation research. The role of 
GC conversion and the constitutive intra-organ bioavailability of cortisol to tolerance remains 
currently unexplored. Given that the activating 11-HSD1 enzyme is preferentially expressed in liver 
and the inactivating 11-HSD2 enzyme in kidney (Hardy et al., 2012), it may not be coincidental that 
“operational tolerance” is far more frequent in liver than in kidney recipients (Lerut and Sanchez-
Fueyo, 2006). It is, therefore, imperative that the intracrine aspects of steroid metabolism and action 
are further evaluated in solid-organ transplantation.  
Our study has examined differences between KTR in whole blood at gene-expression level. It should 
be noted, however, that alterations in mRNA levels may not automatically translate into altered 
protein levels and enzyme activity and that factors involved in the regulation of the GC response 
extend into posttranslational protein modifications, GR affinity to GC, availability of chaperons 
inactivating GR in the cytoplasm, GR translocation into the nucleus and GR interactions with other 
transcription factors involved in the pro- and anti-inflammatory processes. Nevertheless, our study 
reveals that differences in steroid conversion and receptor genes between tolerant, CR and stable 
patients are comparable or even larger than the differences for well-established tolerance 
associated genes such as FOXP3 and the B-cell receptor genes IGKV4-1 and IGKV1D-13 (Figure 4), 
indicating that steroid conversion and receptor genes should be taken into consideration when 
genes are selected for clinically-relevant gene-expression signatures.  
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Our work also directs future studies in cell subsets based on the demonstrated association of the GR-
gene (NR3C1) with neutrophils and of the MR-gene (NR3C2) with T-cells (Figure 6), locations 
previously noted (Armanini et al., 1988,Nakagawa et al., 1998), but with insufficiently unexplored 
role in transplantation. Immune cell functional studies in transplantation are often confined to 
PBMC, due to their analytical stability, disregarding a potential contribution of neutrophils and the 
innate immune response to the immunological processes involved in tolerance and rejection. Our 
work highlights the need to address this gap. It also illustrates how analysis of peripheral whole 
blood can give an in vivo insight into pathological states in the human with minimally invasive 
means, reflecting the net effect of simultaneously activated immunological pathways.   
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Figure Captions 
Figure 1 Comparison of drug-adjusted expression of individual steroid conversion and 
receptor genes between clinical groups 
Drug-adjusted gene expression (fold difference on log2 scale) was derived as the difference 
between the observed –Ct values (relative to hypoxanthine phosphoribosyltransferase (HPRT)) and 
the values predicted by linear regression models, based on stable patients, with a binary indicator 
for prednisolone intake and categorical indicators for intake of calcineurin inhibitors (CNI) (off, 
cyclosporine, tacrolimus) and anti-proliferative drugs (off, azathioprine, mycophenolate 
mofetil/mycophenolic acid); Tolerant – tolerant patients (n=17); Stable – stable patients (n=190); CR 
– chronic rejector patients (n=37); HC – healthy controls (n=14); Black dots – patients receiving 
prednisolone; Gene symbols are explained with full gene names in Table S1; NR3C1v2 – difference 
between the expression of NR3C1 and NR3C2 on log2 scale (equivalent to the ratio on a linear scale); 
p-values were derived from Wilcoxon-Mann-Whitney tests. 
 
Figure 2 Regression coefficients for steroid conversion and receptor genes jointly 
examined in multivariable models 
Group comparisons were based on penalised logistic regression (elastic net penalty, alpha 0.7); A. – 
a model comparing tolerant (n=17) with stable (n=190) patients; B. – a model comparing chronic 
rejector (CR) (n=37) with stable patients; Regression coefficients represent summaries (median, 
interquartile range (grey box), 2.5th - 97.5th centile (vertical segments)) of 50 repeats of five-fold 
cross-validation cycles (numeric details in Table S2) (absolute values indicate gene importance, for 
further details on the interpretation of the centile ranges see Section 2.3.2.); Gene symbols are 
explained with full gene names in Table S1. 
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Figure 3 Predicted probability of tolerance and chronic rejection based on steroid 
conversion and receptor gene signatures 
Predicted probabilities were derived from multivariable penalised logistic regression models (elastic 
net penalty, alpha 0.7) with the training groups for each comparison between the clinical groups 
indicated in the plot title (the remaining two groups served as validation sets) and regression 
coefficients (Figure 2) derived as the median of 50 repeats of five-fold cross-validation cycles; 
Tolerant – tolerant patients (n=17); Stable – stable patients (n=190); CR – chronic rejector patients 
(n=37); HC – healthy controls (n=14); black dots – patients receiving prednisolone; T1 –timepoint 1 
training dataset (A,C) ; T2 – timepoint 2 validation dataset (B,D); p-values were derived from 
Wilcoxon-Mann-Whitney tests. 
 
Figure 4 Regression coefficients for steroid conversion and receptor genes and tolerance-
associated genes jointly examined in multivariable models 
Comparisons between clinical groups were based on penalised logistic regression (elastic net 
penalty, alpha 0.7), including 95 genes (5 steroid conversion and receptor genes, 88 tolerance-
associated genes, 2 genes used as reference in the literature); A. – a model comparing tolerant 
(n=13) vs stable (n=171) patients; B. – a model comparing chronic rejectors (CR) (n=34) with stable 
patients; Regression coefficients represent summaries (median, interquartile range (grey box), 2.5th 
- 97.5th centile (vertical segments)) of 50 repeats of five-fold cross-validation cycles (numeric details 
in Table S3) (absolute values indicate gene importance, for further details on the interpretation of 
the centile ranges see Section 2.3.2.); Only classification-relevant genes are labelled for each group 
comparison;  Gene symbols are explained with full gene names in Table S1 (steroid conversion and 
receptor genes have been listed first). 
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Figure 5 Predicted probability of tolerance or chronic rejection based on steroid 
conversion and receptor and tolerance-associated gene signatures 
Predicted probabilities are based on multivariable penalised logistic regression models (elastic net 
penalty, alpha 0.7) with the training groups for each comparison between the clinical groups 
indicated in the plot title (the remaining groups served as validation sets) and regression coefficients 
(Figure 4) derived as the median of 50 repeats of five-fold cross-validation cycles; Tolerant – tolerant 
patients (n=13); Stable – stable patients (n=171); CR – chronic rejector patients (n=34); HC – healthy 
controls (n=11); black dots – patients receiving prednisolone; T1 – timepoint 1 training dataset (A,C) 
; T2 – timepoint 2 validation dataset (B,D); p-values were derived from Wilcoxon-Mann-Whitney 
tests. 
 
Figure 6 Correlation heatmap of drug-adjusted expression of steroid conversion and 
receptor genes, classification-relevant tolerance-associated genes, neutrophils and 
lymphocyte counts 
Drug-adjusted gene expression (fold difference on log2 scale) and drug-adjusted cell counts were 
derived as the difference between the observed values and the values predicted by linear regression 
models, based on stable patients, with a binary indicator for prednisolone intake and categorical 
indicators for intake of calcineurin inhibitors (CNI) (off, cyclosporine, tacrolimus) and anti-
proliferative drugs (off, azathioprine, mycophenolate mofetil/mycophenolic acid); the dataset 
comprised tolerant, stable and chronic rejector patients at timepoint 1; the correlation matrix was 
based on pairwise Pearson correlation coefficients; * blood cell subtypes; ** steroid conversion and 
receptor genes; Gene symbols are explained with full gene names in Table S1.  
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Table 1. Multivariable model performance evaluated with AUC 
Time Signatures Tolerance Chronic rejection 
point Comparison g5 g17 g2 g15 
T1 Tolerant/CR* vs Stable 
(train) 
0.87  
(0.79 - 0.94) 
0.98  
(0.96 – 1.00) 
0.65  
(0.55 - 0.75) 
0.88  
(0.83 - 0.94) 
T1 Tolerant/CR* vs Stable 
(cross-validation)** 
0.82  
(0.78 - 0.85) 
0.82  
(0.73 - 0.89) 
0.57  
(0.50 - 0.62) 
0.73  
(0.68 - 0.77) 
T2 Tolerant/CR* vs Stable 
(test) 
0.78  
(0.66 - 0.90) 
0.95  
(0.88 – 1.00) 
0.75  
(0.61 - 0.89) 
0.90  
(0.80 – 1.00) 
T1 Tolerant vs CR 
(train+test) 
0.86  
(0.77 - 0.96) 
0.96  
(0.91 – 1.00) 
0.77  
(0.64 - 0.90) 
0.93  
(0.82 – 1.00) 
T2 Tolerant vs CR 
(test) 
0.94  
(0.86 – 1.00) 
0.98  
(0.93 – 1.00) 
0.85  
(0.70 – 1.00) 
0.96  
(0.89 – 1.00) 
*- comparison of tolerant vs stable patients for the tolerance signatures and chronic rejector (CR) vs 
stable patients for the CR signatures; AUC - area under the ROC (receiver operating characteristics) 
curve (95% DeLong confidence interval, except for cross-validation (see below)); Signature – gene-
expression signature based on penalised logistic regression with elastic net penalty (alpha 0.7) (gene 
selection was based on a median regression coefficient >0.001 or <-0.001 from 50 group-stratified 
five-fold cross-validation repeats); g2 – 2-gene signature of CR based on HSD11B2 and NR3C1 
expression (Figure 2B); g5 - 5-gene signature of tolerance, based on H6PD, HSD11B1, HSD11B2, 
NR3C1 and NR3C2 expression (Figure 2A); g15 – 15-gene signature of CR based on the expression of  
HSD11B2, NR3C1 and a selection of 13 tolerance-associated genes (Figure 4B);  g17 – 17-gene 
signature of tolerance based on the expression of HSD11B1, NR3C1 and NR3C2 and a selection of 14 
tolerance-associated genes (Figure 4A); Gene symbols are explained with full gene names in Table 
S1; train – AUC of predicted probability of tolerance (tolerance signature) or CR (CR signature) for 
the training dataset – timepoint 1 (T1); cross-validation – median AUC (2.5th – 97.5th centile) from 50 
repeats of five-fold cross-validation cycles with the training data; test - AUC of the predicted 
probability of tolerance or CR for the validation dataset – timepoint 2 (T2); train+test – AUC of the 
predicted probability of tolerance comparing (at timepoint 1) the training tolerant patients with the 
CR patients (which do not participate in the tolerance signature development) and AUC of the 
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predicted probability of CR comparing (at timepoint 1) the tolerant patients (which do not 
participate in the CR signature development) with the training CR patients.  
